Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial

BACKGROUND: The phase II AFUGEM GERCOR trial aimed to assess the efficacy of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine (gemcitabine group) or simplified leucovorin and fluorouracil (sLV5FU2 group) in patients with previously untreated metastatic pancreatic cancer. Results...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Med
Hlavní autoři: Charton, Emilie, Bachet, Jean‐Baptiste, Hammel, Pascal, Desramé, Jérôme, Chibaudel, Benoist, Cohen, Romain, Debourdeau, Philippe, Dauba, Jérome, Lecomte, Thierry, Seitz, Jean‐François, Tournigand, Christophe, Aparicio, Thomas, Guerin‐Meyer, Véronique, Taieb, Julien, Volet, Julien, Louvet, Christophe, Anota, Amélie, Bonnetain, Franck
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Clinical Cancer Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6718524/
https://ncbi.nlm.nih.gov/pubmed/31314957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2311
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky